|
|
|
|
| LEADER |
03188nam a22005055i 4500 |
| 001 |
978-1-4020-7920-7 |
| 003 |
DE-He213 |
| 005 |
20151204191130.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2004 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781402079207
|9 978-1-4020-7920-7
|
| 024 |
7 |
|
|a 10.1007/b113185
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC254-282
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 245 |
1 |
0 |
|a Hematopathology in Oncology
|h [electronic resource] /
|c edited by William G. Finn, LoAnn C. Peterson.
|
| 264 |
|
1 |
|a Boston, MA :
|b Springer US,
|c 2004.
|
| 300 |
|
|
|a XII, 298 p. 33 illus.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Cancer Treatment and Research,
|x 0927-3042 ;
|v 121
|
| 505 |
0 |
|
|a mRNA Microarray Analysis in Lymphoma and Leukemia -- Myelodysplastic/Myeloproliferative Diseases -- Relevance of Pathologic Classifications and Diagnosis of Acute Myeloid Leukemia to Clinical Trials and Clinical Practice -- Molecular Cytogenetic Studies for Hematological Malignancies -- The Plasma Cell Dyscrasias -- Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders -- Laboratory Hematology Practice -- Role of Fine Needle Aspiration in Lymphoma -- Angiogenesis in Leukemia and Lymphoma -- Clinical Flow Cytometry -- Hodgkin Lymphoma.
|
| 520 |
|
|
|a Hematologist/oncologists rely heavily upon the discipline of hematopathology for the care and management of their patients. Whether interpreting a lymph node or bone marrow biopsy, directing a high throughput automated hematology laboratory, or translating testing modalities from the research bench to the clinical laboratory, hematopathologists and other laboratory medicine specialists provide a steady stream of critical data for the clinical practitioner. Recently the rapid advances in diagnosis and treatment of hematological disorders including the need to evaluate patients' eligibility for and monitor responses to rapidly evolving targeted therapies have made the close collaboration between pathologists and clinician practitioners even more essential. Our goal is to provide outstanding reviews of selected topics in hematopathology in a format that provides both general and historical background, as well as an overview of the state-of-the-art in diagnostic hematopathology, with an eye on future potential and future developments.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Hematology.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
|
0 |
|a Pathology.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Hematology.
|
| 650 |
2 |
4 |
|a Pathology.
|
| 700 |
1 |
|
|a Finn, William G.
|e editor.
|
| 700 |
1 |
|
|a Peterson, LoAnn C.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781402079191
|
| 830 |
|
0 |
|a Cancer Treatment and Research,
|x 0927-3042 ;
|v 121
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/b113185
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 912 |
|
|
|a ZDB-2-BAE
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
